Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease

Eur J Cancer Clin Oncol. 1985 May;21(5):607-13. doi: 10.1016/0277-5379(85)90089-6.

Abstract

A group of 13 patients with advanced, diffuse Hodgkin's disease, poorly responding to the most widely employed primary chemotherapy regimens, were treated with massive chemotherapy (MCH) followed by rescue with non-frozen autologous bone marrow infusion (ABMT). Complete remission (CR) was obtained in 8/13 patients (61.5%) and partial remission in two. Hematopoietic recovery occurred in 12 cases. These preliminary results would seem to indicate that MCH with non-frozen ABMT may be successfully used in patients with resistant or relapsed Hodgkin's disease.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Blood Cell Count
  • Bone Marrow Diseases / prevention & control
  • Bone Marrow Transplantation*
  • Carmustine / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Hodgkin Disease / blood
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / mortality
  • Humans
  • Male

Substances

  • Etoposide
  • Cyclophosphamide
  • Carmustine